SCHEMBL1635563

SCHEMBL1635563

Nc1ccc2nc3ccc(=O)cc-3oc2c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 13/20 0.68
CYP1A2 P05177 1/20 0.59
KDM4E B2RXH2 2/20 0.47
MEN1 O00255 2/20 0.47
ALDH1A1 P00352 2/20 0.47
MAPT P10636 2/20 0.47
RAB9A P51151 2/20 0.47
KMT2A Q03164 2/20 0.47
NPC1 O15118 1/20 0.47
GLA P06280 1/20 0.47
GAA P10253 1/20 0.47
HPGD P15428 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
L3MBTL1 Q9Y468 2/20 0.46
ALPL P05186 1/20 0.46
POLB P06746 1/20 0.46
ALPI P09923 1/20 0.46
ALPG P10696 1/20 0.46
RECQL P46063 1/20 0.46
SNCA P37840 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13648662 0.83 APP (0.55) APPCYP1A2KDM4EMEN1ALDH1A1
SCHEMBL14243596 0.81 APP (0.68) APPCYP1A2KDM4EMEN1ALDH1A1
SCHEMBL1093966 0.81 APP (0.68) APPCYP1A2KDM4EMEN1ALDH1A1
SCHEMBL3363350 0.81 RAB9A (0.47) APPCYP1A2KDM4EMEN1ALDH1A1
SCHEMBL8066 0.81 APP (1.00) APPCYP1A2MEN1KMT2APOLB
SCHEMBL29456578 0.80 APP (0.97) APPCYP1A2MEN1KMT2APOLB
SCHEMBL29456527 0.80 APP (0.67) APPCYP1A2KDM4EMEN1ALDH1A1
SCHEMBL7113427 0.80 APP (0.97) APPCYP1A2MEN1KMT2APOLB
Ammonia Solution, Strong SCHEMBL29419058 0.80 APP (0.97) APPCYP1A2MEN1KMT2APOLB
SCHEMBL1095367 0.80 APP (0.97) APPCYP1A2MEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240131047-A1 SMALL MOLECULE INHIBITORS OF CD38 AS IMMUNOSUPPRESSANTS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2024-04-25 US disclosed
EP-4288053-A1 SMALL MOLECULE INHIBITORS OF CD38 AS IMMUNOSUPPRESSANTS Ohio State Innovation Foundation (US) 2023-12-13 EP disclosed
WO-2022170265-A1 SMALL MOLECULE INHIBITORS OF CD38 AS IMMUNOSUPPRESSANTS OHIO STATE INNOVATION FOUNDATION (US) 2022-08-11 WO disclosed
CN-108440482-A A kind of preparation method and application of the near-infrared ratio fluorescent probe of real-time detection mercury ion 军事科学院军事医学研究院环境医学与作业医学研究所 2018-08-24 CN disclosed
US-20170334865-A1 DDR2 INHIBITORS AND METHODS OF USING WASHINGTON UNIVERSITY (US) 2017-11-23 US disclosed
US-20170334865-A1 DDR2 INHIBITORS AND METHODS OF USING WASHINGTON UNIVERSITY (US) 2017-11-23 US disclosed
EP-1786828-B1 NOVEL ENZYMATIC SUBSTRATES DERIVED FROM PHENOXAZINONE AND THEIR USE AS DEVELOPER IN DETECTION OF MICRO-ORGANISM WITH PEPTIDASE ACTIVITY BIOMERIEUX SA (FR) 2012-01-11 EP disclosed
US-7932050-B2 Enzymatic substrates derived from phenoxazinone and their use as developers in detection of microorganisms with peptidase activity BIOMERIEUX (FR) 2011-04-26 US disclosed
US-20100028926-A1 Novel enzymatic substrates derived from phenoxazinone and their use as developer in detection of microorganisms with peptidase activity BIOMERIEUX (FR) 2010-02-04 US disclosed
US-7626018-B2 Enzymatic substrates derived from phenoxazinone and their use as developer in detection of microorganisms with peptidase activity bioMérieux (FR) 2009-12-01 US disclosed
US-20080293094-A1 Novel Enzymatic Substrates Derived from Phenoxazinone and Their Use as Developer in Detection of Microorganisms with Peptidase Activity BIOMERIEUX (FR) 2008-11-27 US disclosed
EP-1786828-A1 NOVEL ENZYMATIC SUBSTRATES DERIVED FROM PHENOXAZINONE AND THEIR USE AS DEVELOPER IN DETECTION OF MICRO-ORGANISM WITH PEPTIDASE ACTIVITY BIOMERIEUX (FR) 2007-05-23 EP disclosed
WO-2006030119-A1 NOVEL ENZYMATIC SUBSTRATES DERIVED FROM PHENOXAZINONE AND THEIR USE AS DEVELOPER IN DETECTION OF MICRO-ORGANISM WITH PEPTIDASE ACTIVITY bioMérieux (FR) 2006-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170334865-A1 DDR2 INHIBITORS AND METHODS OF USING DDR2, DDR1, DDRGK1 APP 3057/4885CYP1A2 4799/4885KDM4E 3873/4885
US-20240131047-A1 SMALL MOLECULE INHIBITORS OF CD38 AS IMMUNOSUPPRESSANTS CD38, CD2, CD58 APP 4091/4885CYP1A2 4276/4885KDM4E 2787/4885
US-20080293094-A1 Novel Enzymatic Substrates Derived from Phenoxazinone and Their Use as Developer in Detection of Microorganisms with Peptidase Activity PEPD, CTRL, PREP APP 210/4885CYP1A2 174/4885KDM4E 2742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.